Trial and error

Covid-19 transformed clinical trials practically overnight, with remote testing and quicker approvals suddenly becoming a reality the world over. These shifts aren’t hard to understand. Eager to defeat the pandemic as quickly as possible, researchers were happy to embrace change for financial and efficiency reasons. But with the pandemic finally passing into history, can we expect the revolutions of 2020 to transform clinical trials over the long term? Andrea Valentino talks to Professor Kenneth Getz, at the Tufts Center for the Study of Drug Development, to learn more.